Blueprint Medicines Corp.
(NASDAQ : BPMC)

( )
BPMC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.37%86.271.3%$1274.24m
AMGNAmgen Inc.
0.97%203.881.2%$676.03m
GILDGilead Sciences, Inc.
0.77%69.180.9%$577.80m
LOXOLoxo Oncology Inc
0.11%233.5012.7%$474.39m
BIIBBiogen Inc.
-0.27%337.421.3%$459.87m
ILMNIllumina, Inc.
0.87%312.753.5%$351.51m
VRTXVertex Pharmaceuticals Incorporated
2.19%194.701.9%$332.94m
REGNRegeneron Pharmaceuticals, Inc.
0.35%418.842.6%$322.26m
ALXNAlexion Pharmaceuticals, Inc.
2.12%117.052.0%$239.80m
TSROTESARO, Inc.
0.03%74.9614.4%$196.22m
AAgilent Technologies, Inc.
2.10%72.311.5%$166.45m
EXASExact Sciences Corporation
4.19%78.8025.3%$156.07m
INCYIncyte Corporation
-0.32%78.422.5%$153.20m
SRPTSarepta Therapeutics, Inc.
1.22%122.8015.4%$142.40m
LGNDLigand Pharmaceuticals Incorporated
6.49%117.9023.1%$123.00m

Company Profile

Blueprint Medicines Corp. engages in the research, development, and commercialization of pharmaceutical products. It focuses on medicines to improve the lives of patients with genomically defined cancers and rare diseases. Its portfolio includes BLU-285 and BLU-554 for the treatment of gastrointestinal stromal tumors, systemic mastocytosis, and leukemia. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy in October 2008 and is headquartered in Cambridge, MA.